Clinical trial
A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease.
NCT02027805 is registered in ClinicalTrials.gov with Xenikos as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease.
- Lead sponsor
- Xenikos
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 5, 2014
- Completion date
- November 3, 2016
- Enrollment
- 20 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.